ArticleJournal for immunotherapy of cancer2026
Propionate promotes CD8
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundShort-chain fatty acids (SCFAs) produced by the gut microbiota are increasingly recognized as regulators of host immunity, yet the role of individual SCFAs in shaping the tumor immune microenvironment in colorectal cancer (CRC) remains poorly defined. This study aims to investigate the role of propionate in antitumor immunity and immunotherapy responsiveness in CRC.
methodsSCFA levels, systemic inflammatory cytokine levels, and immune cell subsets were quantified in peripheral blood and tumor tissues from patients with CRC and healthy controls. Syngeneic microsatellite instability-high (MSI-H) and microsatellite stable (MSS) murine CRC models were used to evaluate the therapeutic efficacy of propionate alone and in combination with anti-programmed death-ligand 1 (PD-L1) blockade. CD8
resultsPropionate levels were inversely associated with systemic inflammation and positively correlated with intratumoral CD8
conclusionsThis study revealed the role of propionate in regulating the tumor immune microenvironment in CRC, suggesting propionate as a promising strategy to overcome immune exclusion and enhance the efficacy of immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.